Effect of the Small Molecule Inhibitor of Kallikrein-Related Peptidase 7 Against Ovarian CancerA

Hongjuan SHI; Wei LIU; Liling HU; Xiao TAN

doi:10.3881/j.issn.1000-503X.16231

PDF(4196 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (3) : 366-374. DOI: 10.3881/j.issn.1000-503X.16231

Original Articles

Effect of the Small Molecule Inhibitor of Kallikrein-Related Peptidase 7 Against Ovarian CancerA

Hongjuan SHI ¹^,² ,
Wei LIU ³ ,
Liling HU ⁴ ,
Xiao TAN ¹

Author information +

History +

Abstract

Objective To investigate the effect of the small molecule inhibitor C42 of kallikrein-related peptidase 7(KLK7)on ovarian cancer with elevated expression of KLK7 and evaluate the feasibility of C42 as a new therapeutic strategy for ovarian cancer.Methods The CCK-8 assay,flow cytometry,cell scratch assay,Transwell assay,and Western blotting were employed to assess the effects of C42 on the proliferation,migration,and invasion of the ovarian cancer cell line SKOV3,which was characterized by high KLK7 expression.Additionally,a subcutaneous xenograft model of ovarian cancer was established with SKOV3 cells in nude mice to evaluate the effects of C42 on the tumor growth and metastasis.The expression levels of proteins associated with tumor metastasis and invasion in the tumor tissue were examined by immunohistochemical techniques.Results The cellular experiment showed that C42 suppressed the proliferation,migration,and invasion(all P<0.001)of SKOV3 cells,compared with the control group.The animal experiment showed that compared with the control group,the 10.2 mg/kg C42 group exhibited a decreased tumor weight(P=0.009) and attenuated liver metastases.Immunohistochemical staining revealed that the 10.2 mg/kg C42 group demonstrated down-regulated expression of the tumor proliferation marker Ki-67(P=0.002)and the tumor metastasis and invasion-associated proteins such as matrix metalloproteinase-9(P=0.027)and Vimentin(P=0.039).Conclusion The small molecule inhibitor C42 of KLK7 effectively suppresses the proliferation,migration,and invasion of ovarian cancer SKOV3 cells.

Key words

ovarian cancer / kallikrein-related peptidase 7 / SKOV3 cell / targeted therapy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Hongjuan SHI , Wei LIU , Liling HU , et al. Effect of the Small Molecule Inhibitor of Kallikrein-Related Peptidase 7 Against Ovarian CancerA[J]. Acta Academiae Medicinae Sinicae. 2025, 47(3): 366-374 https://doi.org/10.3881/j.issn.1000-503X.16231

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer[J]. BMJ, 2020,371:m3773.DOI:10.1136/bmj.m3773. Cited in this article [1]

[2]	Singh N, Jayraj AS, Sarkar A, et al. Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer[J]. Expert Opin Pharmacother, 2023, 24(1):49-64.DOI:10.1080/14656566.2022.2112030. Cited in this article [1]

[3]	Yang L, Xie HJ, Li YY, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer(Review)[J]. Oncol Rep, 2022, 47(4):82.DOI:10.3892/or.2022.8293. Cited in this article [1]

[4]	Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer[J]. Int J Clin Oncol, 2022, 27(7):1120-1126.DOI:10.1007/s10147-022-02169-x. Cited in this article [1]

[5]	Siminiak N, Czepczyński R, Zaborowski MP, et al. Immunotherapy in ovarian cancer[J]. Arch Immunol Ther Exp(Warsz), 2022, 70(1):19.DOI:10.1007/s00005-022-00655-8. Cited in this article [1]

[6]	Schoutrop E, Moyano-Galceran L, Lheureux S, et al. Molecular,cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment[J]. Semin Cancer Biol, 2022, 86(Pt 3):207-223.DOI:10.1016/j.semcancer.2022.03.027. Cited in this article [1]

[7]	Tamir A, Jag U, Sarojini S, et al. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes[J]. J Ovarian Res, 2014,7:109.DOI:10.1186/s13048-014-0109-z. Cited in this article [1]

[8]	Prezas P, Arlt MJ, Viktorov P, et al. Overexpression of the human tissue kallikrein genes KLK4,5,6,and 7 increases the malignant phenotype of ovarian cancer cells[J]. Biol Chem, 2006, 387(6):807-811.DOI:10.1515/BC.2006.102. Cited in this article [1]

[9]	Chen E, Zhu H, Yang Y, et al. Analysis of expression and prognosis of KLK7 in ovarian cancer[J]. Open Med(Wars), 2020, 15(1):932-939.DOI:10.1515/med-2020-0139. Cited in this article [1]

[10]	Yousef GM, Scorilas A, Katsaros D, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer[J]. J Clin Oncol, 2003, 21(16):3119-3126.DOI:10.1200/JCO.2003.09.111. Cited in this article [1]

[11]	Xiang F, Wang Y, Cao C, et al. The role of kallikrein 7 in tumorigenesis[J]. Curr Med Chem, 2022, 29(15):2617-2631.DOI:10.2174/0929867328666210915104537. Cited in this article [1]

[12]	Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains[J]. Biochim Biophys Acta, 2011, 1813(8):1525-1531.DOI:10.1016/j.bbamcr.2011.05.007. Cited in this article [1]

[13]

Dong

, Tan

, Loessner

, et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1)integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma[J]. Cancer Res, 2010, 70(7):2624-2633.DOI:10.1158/0008-5472.CAN-09-3415.

Cited in this article [1]

[14]	Schmitt M, Magdolen V, Yang F, et al. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases(KLK)in female and male reproductive organ malignancies[J]. Radiol Oncol, 2013, 47(4):319-329.DOI:10.2478/raon-2013-0053. Cited in this article [1]

[15]	Gong W, Liu Y, Diamandis EP, et al. Prognostic value of kallikrein-related peptidase 7(KLK7)mRNA expression in advanced high-grade serous ovarian cancer[J]. J Ovarian Res, 2020, 13(1):125.DOI:10.1186/s13048-020-00725-5. Cited in this article [1]

[16]	Loessner D, Goettig P, Preis S, et al. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer[J]. Expert Opin Ther Targets, 2018, 22(9):745-763.DOI:10.1080/14728222.2018.1512587. Cited in this article [1]

[17]	Bhattarai N, Kumbhar AA, Pokharel YR, et al. Anticancer potential of coumarin and its derivatives[J]. Mini Rev Med Chem, 2021, 21(19):2996-3029.DOI:10.2174/1389557521666210405160323. Cited in this article [1]

[18]	Chandra A, Pius C, Nabeel M, et al. Ovarian cancer:current status and strategies for improving therapeutic outcomes[J]. Cancer Med, 2019, 8(16):7018-7031.DOI:10.1002/cam4.2560. Cited in this article [1]

[19]	Kaya R, Takanashi H, Nakajima A, et al. Prognostic significance of Ki-67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer[J]. J Obstet Gynaecol Res, 2021, 47(11):3979-3989.DOI:10.1111/jog.14981. Cited in this article [1]

[20]	Mrozik KM, Blaschuk OW, Cheong CM, et al. N-cadherin in cancer metastasis,its emerging role in haematological malignancies and potential as a therapeutic target in cancer[J]. BMC Cancer, 2018, 18(1):939.DOI:10.1186/s12885-018-4845-0. Cited in this article [1]

[21]	Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer[J]. Biomed Pharmacother, 2019,118:109320.DOI:10.1016/j.biopha.2019.109320. Cited in this article [1]

[22]	Kalali D. The role of the matrix metalloproteinase-9 gene in tumor development and metastasis:a narrative review[J]. Glob Med Genet, 2023, 10(2):48-53.DOI:10.1055/s-0043-1768166. Cited in this article [1]

[23]	Huang H. Matrix metalloproteinase-9(MMP-9)as a cancer biomarker and MMP-9 biosensors:recent advances[J]. Sensors(Basel), 2018, 18(10):3249.DOI:10.3390/s18103249. Cited in this article [1]

[24]	Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011, 68(18):3033-3046.DOI:10.1007/s00018-011-0735-1. Cited in this article [1]

[25]	Bisyris E, Zingkou E, Kordopati GG, et al. Generation of a quenched phosphonate activity-based probe for labelling the active KLK7 protease[J]. Org Biomol Chem, 2021, 19(31):6834-6841.DOI:10.1039/d1ob01273h. Cited in this article [1]

[26]	Song XF, Fan J, Liu L, et al. Coumarin derivatives with anticancer activities:an update[J]. Arch Pharm(Weinheim), 2020, 353(8):e2000025.DOI:10.1002/ardp.202000025. Cited in this article [1]